Developer of botanically-derived drugs, also some health food products

First drug development company listed on the Taiwan stock market, back in 2008.

Member of the Maywufa Group, involved in health products, drug distribution, etc.

Built Taiwan’s first GMP sterile botanical drug manufacturing facility in compliance with PIC/S and FDA regulations.

Success story is ‘PG2’ lyophilized injection, approved by the TFDA for fatigue in cancer patients, and currently undergoing FDA Phase II trial for the same.

Other drugs in the pipeline include:
PHN131 (for moderate to severe pain)
PHN014 (for acute ischemia stroke)
PHN031 (for osteoporosis prevention)
PHN033 (for diabetic nephropathy treatment)
PHN015 (for hemorrhage stroke)
PHN013 (for idiopathic thrombocytopenic purpura (ITP))
PHDC-01 (stem cell treatment for bone growth)
PHDC-02 (stem cell treatment for cartilage growth)